Latest Oncology News

Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma

Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma

April 25th 2024

Ryan Scott

Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.

More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study

More Than 25% of Cancer Survivors Report Significant Levels of Disability After Cancer Diagnosis, According to New Study

April 25th 2024

Dana-Farber Cancer Institute

A survey of cancer survivors found that over a quarter had a physical disability impairing mobility and almost 10% had a disability affecting self-care.

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

April 25th 2024

Megan Hollasch

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection

Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection

April 25th 2024

Courtney Flaherty

Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.

Camidge and Su Compare Lung Cancer Treatment Strategies in China and the United States

Camidge and Su Compare Lung Cancer Treatment Strategies in China and the United States

April 25th 2024

D. Ross Camidge, MD, PhD

Drs Camidge and Su discuss the aspects of medicine that strengthened Dr Su’s interest in oncology and the details of delivering lung cancer care in China.

Latest Oncology Videos

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC
DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC
Dr Pantin on the Evolving Treatment Paradigm in PNH
Monitoring and AE Management Strategies with Fruquintinib in CRC
Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology
Dr Hafez on the Design of the FeDeriCa Trial in HER2+ Early Breast Cancer
Dr Eroglu on the Safety Profile of Ceritinib Plus Trametinib in Advanced Melanoma
Dr. Annie Im: How to Treat Acute Myeloid Leukemia in 2024
Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple Myeloma
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Dr Jain on Unmet Needs in the Treatment of Low- and High-Risk MDS
Dr Singh on Unmet Medical Needs in Lung Cancer Treatment
Dr Konecny on PROs With Mirvetuximab Soravtansine in Advanced Ovarian Cancer
Dr Chamie on the FDA Approval of N-803 Plus BCG for BCG-Unresponsive NMIBC
Dr Lattanzi on the Investigation of PARP Inhibitor Combinations in mCRPC
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer
Role of ADCs in HER2-Mutated NSCLC
Dr Ignatz-Hoover on the Evolving Use of Blinatumomab in ALL
Dr. Tiwari on Ongoing Research in HER2+/HER2-Low Breast Cancer
AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes
Dr Townsend on the Genetic Evolutionary Trajectory of Prostate Cancer
Dr Baretti on Entinostat Plus Nivolumab in Advanced PDAC
Dr Simon on the ALK Inhibitor Selection Process in ALK+ NSCLC

All Oncology News

Vebreltinib Receives NMPA Approval in China for MET Fusion+ Glioma

April 25th 2024

Courtney Flaherty

Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.

FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer

April 25th 2024

Caroline Seymour

CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.

Toripalimab NDA Under Review in Hong Kong for Nasopharyngeal Carcinoma

April 25th 2024

Chris Ryan

A new drug application seeking the approval of toripalimab for the treatment of patients with nasopharyngeal carcinoma is under review in Hong Kong.

Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC

April 25th 2024

Ashling Wahner

HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.

Pembrolizumab Plus Chemo Could Represent a New SOC in Advanced/Recurrent Endometrial Cancer

April 25th 2024

Jax DiEugenio

Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.

CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

April 24th 2024

Ashling Wahner

Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.

ChatGPT Displays Potential for Genetic Counseling in Gynecologic Oncology

April 24th 2024

Jax DiEugenio

Jharna M. Patel, MD, discusses the utility of ChatGPT in genetic counseling for patients with gynecologic cancers.

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC

April 24th 2024

Kyle Doherty

Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.

International Pancreatic Cancer Screening Program Displays Practicality

April 24th 2024

Kyle Doherty

The PRECEDE study demonstrated the feasibility of a large-scale early detection and prevention program for pancreatic cancer.

Enzalutamide Receives Go Ahead From European Commission in nmHSPC

April 24th 2024

Kyle Doherty

The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.

What If We Could Eliminate a Major Gastric Cancer Risk Factor?

April 24th 2024

Sylvester Comprehensive Cancer Center

A study by Sylvester Comprehensive Cancer Center assessed the outcomes of a community-based effort to test for and eradicate H. pylori, a major risk factor for gastric cancer.

Dostarlimab/Chemo Receives FDA Priority Review for Expanded Indication in Endometrial Cancer

April 24th 2024

Ashling Wahner

The FDA has granted priority review to dostarlimab plus chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer.

HER2 Expression May Hold the Key to Predicting Survival Outcomes in CRC

April 24th 2024

Courtney Flaherty

Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.

Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer

April 24th 2024

Ryan Scott

Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.

Dr Usmani on the Design of the CARTITUDE-4 Trial in Multiple Myeloma

April 24th 2024

Saad Z. Usmani, MD

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the design of the phase 3 CARTITUDE-4 trial in multiple myeloma.

See All News